Mirum Pharmaceuticals Inc [MIRM] stock is trading at $24.49, up 1.96%. An important factor to consider is whether the stock is rising or falling in short-term value. The MIRM shares have gain 3.90% over the last week, with a monthly amount drifted -1.73%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Mirum Pharmaceuticals Inc [NASDAQ: MIRM] stock has seen the most recent analyst activity on April 17, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $48. Previously, H.C. Wainwright reaffirmed its Buy rating on December 18, 2023, and dropped its price target to $58. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $60 on November 13, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $50 as its price target on October 24, 2023. In a note dated September 20, 2023, JMP Securities initiated an Mkt Outperform rating and provided a target price of $70 on this stock.
Mirum Pharmaceuticals Inc [MIRM] stock has fluctuated between $23.29 and $35.56 over the past year. Currently, Wall Street analysts expect the stock to reach $55 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $24.49 at the most recent close of the market. An investor can expect a potential return of 124.58% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Mirum Pharmaceuticals Inc [NASDAQ:MIRM] reported sales of 186.37M for the trailing twelve months, which represents a growth of 149.24%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.57%, Pretax Profit Margin comes in at -0.86%, and Net Profit Margin reading is -0.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -3.98 and Total Capital is -0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.55 points at the first support level, and at 22.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.03, and for the 2nd resistance point, it is at 25.56.
Mirum Pharmaceuticals Inc [MIRM] reported earnings per share of -$0.66 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.24/share, meaning a difference of -$0.42 and a surprise factor of -175.00%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.57 per share as compared to estimates of -$0.63 per share, a difference of $0.06 representing a surprise of 9.50%.
Ratios To Look Out For
For context, Mirum Pharmaceuticals Inc’s Current Ratio is 4.45. On the other hand, the Quick Ratio is 4.19, and the Cash Ratio is 3.29. Considering the valuation of this stock, the price to sales ratio is 6.12, the price to book ratio is 4.60.
Transactions by insiders
Recent insider trading involved BJERKHOLT ERIC, CHIEF FINANCIAL OFFICER, that happened on Mar 27 ’24 when 2000.0 shares were purchased. PRESIDENT AND COO, Radovich Peter completed a deal on Mar 25 ’24 to sell 4303.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER BJERKHOLT ERIC bought 2000.0 shares on Mar 18 ’24.
